Clinical trials: Topotecan, completed
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and…
- Conditions
- Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00011986
- Testing
- Paclitaxel, Carboplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 4,312 people
- Sponsor
- Gynecologic Oncology Group
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
Lung Cancer
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
- Trial name
- NCT00003917
- Testing
- topotecan hydrochloride
- Where
- 53 sites in United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Ovarian Cancer, Endometrial Cancer
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT00315861
- Testing
- pemetrexed, topotecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Background: Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time.
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms
- Trial name
- NCT02487095
- Testing
- Topotecan, VX-970 (M6620)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan hydrochloride and to see how well they work in treating patients with relapsed or refractory small cell…
- Trial name
- NCT00521144
- Testing
- obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
- Trial name
- NCT00038545
- Testing
- Filgrastim SD/01, Paclitaxel, Topotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplastic Meningitis
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
1. To find the optimal dose of topotecan that can safely be given directly into the spinal fluid (called intrathecal administration) of children whose cancer has spread to the lining of the brain and/or spinal cord. 2.
- Trial name
- PBTC-019 (NCT00674674)
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Cervical Intraepithelial Neoplasia
Meta-analysis of Efficacy of Topotecan
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
- Trial name
- NCT01160185
- Testing
- paclitaxel, cisplatin, topotecan
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
It is assumed, that the patients of the standard arm show a median progression-free survival time of 4.4 months those of the experimental arm of at least 6.9 months.
- Trial name
- TRIAS 2009 (NCT01047891)
- Testing
- Sorafenib
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- JSehouli
Neuroblastoma
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity…
- Trial name
- BEACON (NCT02308527)
- Testing
- Bevacizumab, Temozolomide, Irinotecan
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 225 people
- Sponsor
- University of Birmingham
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Brain and Central Nervous System Tumors
Topotecan in Treating Patients With Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain…
- Trial name
- NCT00003372
- Testing
- topotecan hydrochloride
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk…
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT00588991
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of…
- Trial name
- TAHOE (NCT03061812)
- Testing
- Rovalpituzumab tesirine, Topotecan, Dexamethasone
- Where
- 195 sites in United States, Australia and 31 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
AML
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
- Trial name
- NCT00744081
- Testing
- Glivec, Mitoxantrone, Topotecan
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Goethe University
Colon Cancer
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
- Trial name
- NCT00193167
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells…
- Trial name
- NCT00698516
- Testing
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003065
- Testing
- filgrastim, paclitaxel, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center